Idiopatické střevní záněty zahrnují Crohnovu chorobu aulcerózní kolitidu. Jsou
onemocněním převážně mladého a fertilního věku, kdy i značná část pacientek otěhotní v …

Background Inflammatory bowel diseases (IBD) have a high incidence in the female
population of childbearing age. Ustekinumab (UST) and vedolizumab (VDZ) are used in IBD …

Background & Aims Limited data are available on the consequences of prenatal exposure to
vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and …

Background The prevalence of inflammatory bowel diseases (IBD) is high in women of
childbearing age. Achieving clinical remission from conception to delivery using current …

We read with interest the recently published manuscript by Bell I et al i. entitled I Systematic
review and meta-analysis: Safety of vedolizumab during pregnancy in patients with …

Background The impact of pregnancy on vedolizumab (VDZ) and ustekinumab (UST)
pharmacokinetics is not well defined. Similarly, the time to infant clearance and outcomes …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Background & Aims Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the
infant after in utero exposure remain incompletely defined. We aim to define the antenatal …

Background: Vedolizumab demonstrated different placental pharmacokinetics than other
immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to …